MultiCell Technologies Makes Investor Presentation Available on its Website
Monday September 26, 8:00 am ET
[Tradenride, whether you are an investor or a basher in this company makes no difference to me; because you have proven over and over again on the RagingBull and these threads to be inconsistent, overly emotional, immature, clearly lacking in providing any constructive and objective fundamental knowledge of what makes a biotech company have the potential as an investment, but worst of all, you appear dishonest. I placed you on IGNORE a long time ago! God bless you. Shawn (real name)
LINCOLN, R.I.--(BUSINESS WIRE)--Sept. 26, 2005--MultiCell Technologies, Inc. (OTCBB: MCET - News), a leading adult stem cell company and supplier of immortalized non-tumorigenic human hepatocytes for drug discovery, announced today that a presentation it delivered to the investment community on Thursday evening, September 22nd, is now available on its website at multicelltech.com.
In the presentation, the Company outlined its new therapeutic platform, including its strong intellectual property portfolio, which contains five issued patents in the area of stem cells. The platform, which is based upon Stem Cell Regulation and Growth, Stem Cell Protection and Immunosuppression and Stem Cell Immunostimulation, also has applications for the treatment of Multiple Sclerosis, Type 1 Diabetes and Macular Degeneration.
About MultiCell Technologies, Inc.
MultiCell Technologies is a leading adult stem cell company and supplier of immortalized cell lines validated for drug discovery applications. With its subsidiary MultiCell Immunotherapeutics (MCTI), MultiCell intends to commercialize new therapeutics for the treatment of degenerative neurological disease, metabolic and endocrinological disorders and more. MultiCell holds key patents relating to novel strategies for the isolation of adult human liver cells, and cell clusters or doublets as well as additional patents in the areas of stem cell technology, the Sybiol(TM) synthetic bio-liver therapeutic liver assist device, and immortalized human hepatocytes. MultiCell's stem cells are derived from adult tissues, which avoids the ethical and contamination issues associated with embryonic stem cells. MultiCell's headquarters and research laboratories are at 701 George Washington Highway, Lincoln, Rhode Island 02865. For more information about MultiCell see www.multicelltech.com.
Caution Regarding Forward-Looking Statements
Any statements in this press release about MultiCell's expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). These statements are often, but not always, made through the use of words or phrases such as "believe," "will," "expect," "anticipate," "estimate," "intend," "plan," and "would." MultiCell bases these forward-looking statements on current expectations about future events. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by any forward-looking statement. Some of the risks, uncertainties and assumptions that could cause actual results to differ materially from estimates or projections in the forward-looking statement include, but are not limited to, the risk that the market for our products will not grow as expected, and the risk that our products will not achieve expectations. For additional information about risks and uncertainties we face, see documents we file with the SEC, including our Report on Form 10-KSB for the fiscal year ended November 30, 2004 and all our quarterly and other periodic SEC filings. MultiCell claims the protection of the safe harbor for forward-looking statements under the Act and assumes no obligation and expressly disclaims any duty to update any forward-looking statement to reflect events or circumstances after the date of this news release or to reflect the occurrence of subsequent events.
Contact: MultiCell Technologies, Inc.
Jerry Newmin, 401-333-0610
or
CEOcast, Inc.
Ed Lewis, 212-732-4300
Source: MultiCell Technologies, Inc.
biz.yahoo.com |
